Insights from 2023 ESMO Asia Annual Meeting

 

Insights from 2023 ESMO Asia Annual Meeting
M

ESMO Asia 2023 Insights: "Lenvatinib vs. Sorafenib 2L Therapy in HCC Patients Progressed to Atezolizumab + Bevacizumab"

By Insights from 2023 ESMO Asia Annual Meeting FEATURING Mara Persano
By Insights from 2023 ESMO Asia Annual Meeting FEATURING Mara Persano
0 views
January 17, 2024
Comments 0
Login to view comments. Click here to Login
Gastrointestinal
18:31
Insights from 2023 ESMO Asia Annual Meeting

Enhancing IO Benefit in Upper-Aerodigestive Malignancies - Leveragin…

Feat. B. Henick
08:19
Insights from 2023 ESMO Asia Annual Meeting

Final Analysis of a Ph2 Study of Neoadjuvant S-1 + Oxaliplatin in Ol…

Feat. E. Oki
08:21
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "IMbrave150 Trial - Exploratory Analys…

Feat. M. Kudo
11:13
Insights from 2023 ESMO Asia Annual Meeting

Leveraging the Molecular Biology of HCC in Optimising Response to Im…

Feat. S. L. Chan
06:49
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "Lenvatinib vs. Sorafenib 2L Therapy i…

Feat. M. Persano
06:53
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "AEs as Potential Predictive Factors o…

Feat. M. Persano
06:05
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "Long-Term Outcomes of Intraoperative …

Feat. J. Taieb
21:46
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "Past, Present & Future Clinical M…

Feat. M. Ikeda
18:15
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "Role of IO in Gastric Cancer"

Feat. S. Rha
08:56
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "KEYNOTE-811 Study of Pembro + Trastuz…

Feat. S. Rha
13:51
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "Final Results of the RATIONALE-305 St…

Feat. K. Kato